Consequently, co-targeting lactylation and PD-1/PD-L1 pathways may overcome adaptive resistance by simultaneously disrupting tumor glycolysis and restoring immune effector function, providing a strong mechanistic rationale for combinatorial immunometabolic therapy. This evidence concerns the gene CD274 and neoplasm.